Adding docetaxel or abiraterone (Zytiga) to conventional androgen deprivation therapy (ADT) significantly improved overall survival in men with newly diagnosed metastatic noncastration-resistant prostate cancer (mnCRPC), according to a new guideline from the American Society of Clinical Oncology (ASCO).
Two of three randomized trials showed a survival advantage for the addition of docetaxel to ADT. A third trial that evaluated ADT with or without docetaxel did not demonstrate improved survival with the addition of chemotherapy. Two trials also showed that patients treated with abiraterone plus ADT lived longer than those treated with ADT alone.
“These two additional therapies can substantially change the outcome of men who have newly diagnosed metastatic disease,” guideline panel co-chair Michael J. Morris, MD, of Memorial Sloan-Kettering Cancer Center in New York City, said in a statement. “Having two standards of care allows flexibility and options — these choices and decisions can be negotiated between the patient and the doctor.”
The guideline was published online in the Journal of Clinical Oncology and the ASCO website.